Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 28Neoplasms 15Carcinoma, Non-Small-Cell Lung 7Multiple Myeloma 6Hematologic Neoplasms 6Neoplasm Metastasis 4Lymphoma 4Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Brain Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Skin Neoplasms 2Glioma 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Adenocarcinoma, Follicular 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Myelodysplastic Syndromes 1

Interventions

tremelimumab 1trametinib 1pazopanib 1eribulin 1durvalumab 1HhAntag691 1Gemcitabine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hemangioendothelioma, Epithelioid × trametinib × Clear all
NCT03148275 2024-11-26

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
44 enrolled 12 charts

Hemangioendothelioma, Epithelioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡